---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-001349"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:39:35.901203+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# USPTO allows patent covering levosimendan use in PH-HFpEF through 2040

## Summary
- USPTO Notice of Allowance for patent covering oral (TNX-103), IV, subcutaneous levosimendan, active metabolites, and drug combos for PH-HFpEF.
- Once granted, patent provides IP protection until Dec 2040, may qualify for patent term extension beyond 2040.
- Third patent granted to Tenax since March 2023 protecting levosimendan for PH-HFpEF.
- Phase 3 LEVEL study (NCT05983250) ongoing: 152 patients randomized, primary endpoint 6-minute walk distance at Week 12.

## SEC filing metadata
- accession: 0001654954-24-001349
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424001349/0001654954-24-001349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424001349/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-001349
- JSON: https://secwatch.observer/filing/0001654954-24-001349.json
- Plain text: https://secwatch.observer/filing/0001654954-24-001349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.